CMV Infections in Kidney Transplant Recipients - Dr. Hannah Kaminski (Bordeaux, France)

For stage 2 of our Tour Académique 2023, Dr. Hannah Kaminski discusses novel approaches in diagnosis, prevention and treatment of CMV-disease in renal transplant recipients.

The interview was recorded on May 22th, 2023.

Moderators: Prof. Dominique Guerrot (Rouen, France), Dr. Sarah Morell and Prof. Dr. Gunnar Heine (both Frankfurt, Germany).

Articles discussed:

Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, Kölling K, Stobernack HP, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Champlin RE, Ehninger G; AIC246 Study Team. N Engl J Med. 2014 doi: 10.1056/NEJMoa1309533

Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation.
Isakova T, Xie H, Messinger S, Cortazar F, Scialla JJ, Guerra G, Contreras G, Roth D, Burke GW 3rd, Molnar MZ, Mucsi I, Wolf M. Am J Transplant. 2013
doi: 10.1111/j.1600-6143.2012.04281.x

Reduced exposure to calcineurin inhibitors in renal transplantation.
Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study. N Engl J Med. 2007 doi: 10.1056/NEJMoa067411.

Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA.
JAMA. 2023
doi: 10.1001/jama.2023.9106

Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin.
Cortazar F, Molnar MZ, Isakova T, Czira ME, Kovesdy CP, Roth D, Mucsi I, Wolf M. Am J Transplant. 2012
doi: 10.1111/j.1600-6143.2011.03826.x